This study investigates the continuation of immunotherapy using an investigational medication following initial benefits from a PD-1 or PD-L1 inhibitor in patients with advanced lung cancer, specifically stage IV non-small cell lung cancer (NSCLC). The purpose is to see if this approach, combined with next-line chemotherapy, can extend the time patients live without the disease getting worse, using a standard way of measuring called RECIST 1.1.
Participants in the study will receive the investigational medication along with chemotherapy drugs such as gemcitabine, docetaxel, or pemetrexed (for non-squamous NSCLC only). This study will not include any payments to participants.
- Who can participate: Adults with stage IV non-small cell lung cancer who have previously benefited from PD-1 or PD-L1 inhibitors and have now experienced disease progression may be eligible. Participants must have good performance status and be fit for chemotherapy. Specific genetic mutations must have been treated with standard therapies.
- Study details: Participants will receive the investigational medication alongside chemotherapy. The study will compare these results to historical controls. A placebo is not used in this study.
How understandable was the trial content above?
Hard to understand
Easy to understand
